Cover
Vol. 4 No. 1 (2026)

Published: June 1, 2026

Pages: 1-33

Review Article

Formulation Strategies in Psoriasis: Journey from Traditional Preparations to Advanced Drug Delivery Systems

Shahad Obaid 1 Yasir Qasim 1
1 Department of Pharmaceutics, College of Pharmacy, Al-Nahrain University, Baghdad, Iraq
History
  • Received: December 14, 2025
  • Accepted: January 10, 2026
  • Available Online: June 1, 2026

Abstract

ABSTRACT        Psoriasis (PSO) is an immune-mediated dermatological disorder marked by thick, erythematous, scaly plaques resulting from rapid, excessive cellular growth. Anti-inflammatory agents, immunosuppressant’s, and additional pharmaceuticals serve as the principal therapeutic strategy for psoriasis to alleviate symptoms, diminish inflammation, and inhibit the proliferation and division of epidermal cells. Nevertheless, these drugs generally include disadvantages that impose significant physiological and pathological burdens on patients, including inadequate targeting, brief half-lives, limited absorption rates, and severe toxic side effects. Researchers have recently concentrated significant effort on employing delivery systems for the topical administration of drugs to affected psoriatic skin regions. These systems increase pharmacological efficacy, stability, and penetration. More therapeutic concepts for the treatment of PSO are made possible by the ongoing development of numerous multifunctional topical delivery technologies. This publication reviews various delivery strategies, including hydrogels, nanoparticles, microneedles, micelles, dendrimers, liposomes, nanoemulsions, and vesicles, for topical therapy of PSO and delineates their current developmental status in clinical treatment. It is expected to facilitate the progression of PSO treatment methodologies and provide a benchmark for the development of novel topical delivery systems.

Keywords

References

  1. Armstrong, A.W., et al., Patient Experiences with Psoriatic Disease in the USA: Results from the Psoriasis and Beyond Global Study: W. Armstrong et al.Drugs-Real World Outcomes, 2025: p. 1-15.
  2. Nicolescu, A.C., et al., Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness. Life (Basel), 2022. 12(12).
  3. Chiricozzi, A., et al., Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus. Dermatologic Therapy, 2017. 30.
  4. Metko, D., T. Torres, and R. Vender, Viewpoint about biologic agents for psoriasis: are they immunosuppressants or immunomodulators? Journal of International Medical Research, 2023. 51(6): p. 03000605231175547.
  5. Vincent, N., D.D. Ramya, and H.B. Vedha, Progress in psoriasis therapy via novel drug delivery systems. Dermatology reports, 2014. 6(1): p. 5451.
  6. Mitra, R., et al., Recent advancements in nanoparticle-based topical drug delivery systems for psoriasis treatment. Journal of Drug Targeting, 2025: p. 1-18.
  7. Singh, S., et al., Promising strategies of colloidal drug delivery-based approaches in psoriasis management. Pharmaceutics, 2021. 13(11): p. 1978.
  8. Rendon, A. and K. Schäkel, Psoriasis pathogenesis and treatment. International journal of molecular sciences, 2019. 20(6): p. 1475.
  9. Ogawa, E., et al., Pathogenesis of psoriasis and development of treatment. The Journal of dermatology, 2018. 45(3): p. 264-272.
  10. An, P., et al., Recent advancements and trends of topical drug delivery systems in psoriasis: a review and bibliometric analysis. International Journal of Nanomedicine, 2024: p. 7631-7671.
  11. Boehncke, W.-H. and N.C. Brembilla, Unmet needs in the field of psoriasis: pathogenesis and treatment. Clinical reviews in allergy & immunology, 2018. 55(3): p. 295-311.
  12. Gao, Y., et al., Pathophysiology and treatment of psoriasis: from clinical practice to basic research. Pharmaceutics, 2025. 17(1): p. 56.
  13. Yin, T., T. Zhang, and L. Ma, Immune-related hub genes and their role in psoriasis pathogenesis. Scientific Reports, 2025. 15(1): p. 17765.
  14. Dhabale, A. and S. Nagpure, Types of psoriasis and their effects on the immune system. Cureus, 2022. 14(9).
  15. Ahmad, M.Z., et al., Nanoscale topical pharmacotherapy in management of psoriasis: contemporary research and scope. Journal of Functional Biomaterials, 2022. 14(1): p. 19.
  16. Aijaz, S.F., et al., Deep learning application for effective classification of different types of psoriasis. Journal of Healthcare Engineering, 2022. 2022(1): p. 7541583.
  17. Soni, B., et al., An overview of contemporary and future therapeutic strategies for scalp psoriasis. Current Drug Targets, 2024. 25(5): p. 353-373.
  18. Guo, J., et al., Signaling pathways and targeted therapies for psoriasis. Signal Transduction and Targeted Therapy, 2023. 8(1): p. 437.
  19. Yadav, K., et al., A complex molecular landscape to drug delivery concept for achieving precise therapy in psoriasis. Medicine in Drug Discovery, 2024. 22: p. 100183.
  20. Hoegsberg, T., et al., Topical treatment of psoriasis: questionnaire results on topical therapy as long-term continuous treatment and use on specific body sites. Journal of Dermatological Treatment, 2020. 32: p. 1-26.
  21. Alhammad, I.M., et al., A review on updates in management and treatment of psoriasis. Archives of Pharmacy Practice, 2021. 12(1-2021): p. 74-78.
  22. Sreya, R., et al., Emerging trends in combination strategies with phototherapy in advanced psoriasis management. Inflammopharmacology, 2023. 31(4): p. 1761-1778.
  23. Sbidian, E., et al., Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. Cochrane Database of Systematic Reviews, 2023(7).
  24. Hsieh, T.-S. and T.-F. Tsai, Combination therapy for psoriasis with methotrexate and other oral disease-modifying antirheumatic drugs: a systematic review. Dermatology and Therapy, 2023. 13(4): p. 891-909.
  25. van Huizen, A.M., et al., Methotrexate dosing regimen for plaque-type psoriasis: an update of a systematic review. Journal of Dermatological Treatment, 2022. 33(8): p. 3104-3118.
  26. Pandey, S., et al., A comprehensive review on possibilities of treating psoriasis using dermal cyclosporine. Drug Delivery and Translational Research, 2022. 12(7): p. 1541-1555.
  27. Ilyas, D., et al., A promising topical therapy for treatment of psoriasis: Acitretin encapsulated novel transethosomal gel. Journal of Drug Delivery Science and Technology, 2025. 105: p. 106606.
  28. Brownstone, N.D., et al., Biologic treatments of psoriasis: an update for the clinician. Biologics: Targets and Therapy, 2021: p. 39-51.
  29. Li, Y., et al., Novel Small-Molecule Treatment and Emerging Biological Therapy for Psoriasis. Biomedicines, 2025. 13(4): p. 781.
  30. Shetty, K. and A.P. Sherje, Nano intervention in topical delivery of corticosteroid for psoriasis and atopic dermatitis—a systematic review. Journal of Materials Science: Materials in Medicine, 2021. 32(8): p. 88.
  31. Gisondi, P., et al., Calcipotriol/betamethasone dipropionate for the treatment of psoriasis: mechanism of action and evidence of efficacy and safety versus topical corticosteroids. Journal of Clinical Medicine, 2024. 13(15): p. 4484.
  32. Bodnár, K., et al., Recent approaches for the topical treatment of psoriasis using nanoparticles. Pharmaceutics, 2024. 16(4): p. 449.
  33. Chat, V.S., et al., Management of psoriasis with topicals: Applying the 2020 AAD-NPF guidelines of care to clinical practice. Cutis, 2022. 110(2 Suppl): p. 8-14.
  34. Heath, M.S., et al., Pharmacokinetics of tazarotene and acitretin in psoriasis. Expert opinion on drug metabolism & toxicology, 2018. 14(9): p. 919-927.
  35. Chandraratna, R.A., Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol, 1997. 37(2 Pt 3): p. S12-7.
  36. Mshimesh, B.A., Treatment of Mild to Moderate Plaque Psoriasis with Pimecrolimus, Clobetasol, or Calcipotriol Cream: A comparative study. Journal of the Faculty of Medicine Baghdad, 2016. 58(1): p. 38-45.
  37. Patel, R., et al., Recent Advancements Towards the Use of Vitamin D Isoforms and the Development of Their Synthetic Analogues as New Therapeutics. Biomedicines, 2025. 13(4): p. 1002.
  38. Torsekar, R. and M.M. Gautam, Topical Therapies in Psoriasis. Indian Dermatol Online J, 2017. 8(4): p. 235-245.
  39. Kadian, et al., Dithranol: An Insight into its Novel Delivery Cargos for Psoriasis Management. Current Drug Research Reviews, 2020. 12.
  40. Draelos, Z.D., The efficacy and tolerability of turmeric and salicylic acid in psoriasis treatment. Psoriasis: Targets and Therapy, 2022: p. 63-71.
  41. Kowalska, M.K., et al., Pathogenesis of Psoriasis vulgaris and Current Management and Therapeutic Strategies Including the Role of Emollients—A Review of the Current Literature. Applied Sciences, 2025. 15(12): p. 6811.
  42. Parveen, S., et al., An innovative approach in nanotechnology-based delivery system for the effective management of psoriasis. Current pharmaceutical design, 2022. 28(13): p. 1082-1102.
  43. Zhu, Y., et al., Topical therapy in psoriasis: clinical benefits, advances in novel drug delivery strategies, and gene therapy regimen. Pharmaceutics, 2025. 17(3): p. 283.
  44. Kumari, R., et al., Recent advancement in topical drug delivery for psoriasis: clinical pertinence and potential market. Current Drug Targets, 2021. 22(13): p. 1507-1523.
  45. Moretz, D., Drug Class Update with New Drug Evaluations: Topical Products for Inflammatory Skin Conditions. 2021.
  46. Katare, O.P., et al., Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors. Indian journal of dermatology, venereology and leprology, 2010. 76: p. 612.
  47. Zhang, M., et al., Exploration of and insights into advanced topical nanocarrier systems for the treatment of psoriasis. Frontiers in Medicine, 2022. 9: p. 1017126.
  48. Song, Y., et al., Advancements in the transdermal drug delivery systems utilizing microemulsion-based gels. Current Pharmaceutical Design, 2024. 30(35): p. 2753-2764.
  49. He, E., et al., Transdermal delivery of indirubin-loaded microemulsion gel: Preparation, characterization and anti-psoriatic activity. International Journal of Molecular Sciences, 2022. 23(7): p. 3798.
  50. Ding, Y., et al., Optimization of the Transdermal Delivery System in Astilbin Microemulsion with Improved Stability and Anti-psoriatic Activity. Current Drug Delivery, 2023. 20(3): p. 281-291.
  51. Rahaman, M., et al., Nanoemulsion-Based Therapies: A Promising Approach for Managing Psoriasis. Biomedical Materials & Devices, 2025: p. 1-19.
  52. Khan, R., et al., In vitro and in vivo investigation of a dual-targeted nanoemulsion gel for the amelioration of psoriasis. Gels, 2023. 9(2): p. 112.
  53. Sawarkar, S.P. and V. Yadav, Novel drug delivery strategies and gene therapy regimen as a promising perspective for management of psoriasis. Indian Journal of Dermatology, Venereology and Leprology, 2021. 87(3): p. 333-340.
  54. Jain, S., et al., Exploring the therapeutic potential of functional excipient-based nanoemulgel of fluticasone propionate for the management of psoriasis. Journal of Drug Delivery Science and Technology, 2023. 84: p. 104435.
  55. Dinshaw, I.J., et al., Nanoemulsions: a review on the conceptualization of treatment for psoriasis using a ‘green’surfactant with low-energy emulsification method. Pharmaceutics, 2021. 13(7): p. 1024.
  56. Rashid, S.A., et al., Olive oil based methotrexate loaded topical nanoemulsion gel for the treatment of imiquimod induced psoriasis-like skin inflammation in an animal model. Biology, 2021. 10(11): p. 1121.
  57. Bahadur, S. and M. Sharma, Liposome based drug delivery for the management of psoriasis-A comprehensive review. Current Pharmaceutical Biotechnology, 2023. 24(11): p. 1383-1396.
  58. Kapoor, D.U., et al., Advancing psoriasis drug delivery through topical liposomes. Zeitschrift für Naturforschung C, 2025. 80(3-4): p. 41-60.
  59. Lu, B., J. Zhang, and J. Zhang, Enhancing Transdermal delivery of curcumin-based ionic liquid liposomes for application in psoriasis. ACS Applied Bio Materials, 2023. 6(12): p. 5864-5873.
  60. Paiva-Santos, A.C., et al., Ethosomes as nanocarriers for the development of skin delivery formulations. Pharmaceutical research, 2021. 38(6): p. 947-970.
  61. Peram, M.R., et al., Acitretin-loaded nanoethosomal gel for the treatment of psoriasis: Formulation, optimization, in vitro, and in viv o assessment. Journal of Dispersion Science and Technology, 2024. 46(1): p. 44-61.
  62. Xiong, Z., et al., Preparation and Evaluation of Upadacitinib-Loaded Binary Ethosomal Hydrogel: A Topical Delivery System with Enhanced Stratum Corneum Permeability for Improved Anti-Inflammatory Therapy in Psoriasis. Molecular Pharmaceutics, 2025. 22(10): p. 6025-6037.
  63. Dadwal, N., et al., Quality-by-Design Approach for Investigating the Efficacy of Tacrolimus and Hyaluronic Acid–Loaded Ethosomal Gel in Dermal Management of Psoriasis: In Vitro, Ex Vivo, and In Vivo Evaluation. AAPS PharmSciTech, 2023. 24(8): p. 220.
  64. Monohar, S., et al., Liposomes and Niosomes in Psoriasis Therapy: Emerging Vesicular Approaches for Targeted Treatment. Biomedical Materials & Devices, 2025: p. 1-20.
  65. Qiu, F., et al., Celastrol niosome hydrogel has anti-inflammatory effect on skin keratinocytes and circulation without systemic drug exposure in psoriasis mice. International Journal of Nanomedicine, 2021: p. 6171-6182.
  66. Bhardwaj, P., et al., Cyclosporine and pentoxifylline laden tailored niosomes for the effective management of psoriasis: in-vitro optimization, ex-vivo and animal study. International Journal of Pharmaceutics, 2022. 626: p. 122143.
  67. Almeida, C., et al., Nanodelivery strategies for skin diseases with barrier impairment: focusing on ceramides and glucocorticoids. Nanomaterials, 2022. 12(2): p. 275.
  68. Yang, X., et al., Co-delivery of methotrexate and nicotinamide by cerosomes for topical psoriasis treatment with enhanced efficacy. International Journal of Pharmaceutics, 2021. 605: p. 120826.
  69. Todke, P., et al., ‘Transfersome-embedded-gel’for dual-mechanistic delivery of anti-psoriatic drugs to dermal lymphocytes. Journal of Microencapsulation, 2022. 39(6): p. 495-511.
  70. Katari, O. and S. Jain, Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics for the treatment of psoriasis. Expert opinion on drug delivery, 2021. 18(12): p. 1857-1872.
  71. Pradhan, M., et al., Topical delivery of fluocinolone acetonide integrated NLCs and salicylic acid enriched gel: A potential and synergistic approach in the management of psoriasis. Journal of Drug Delivery Science and Technology, 2021. 61: p. 102282.
  72. Patil, T.S., et al., Recent advancements in topical anti-psoriatic nanostructured lipid carrier-based drug delivery. International journal of molecular sciences, 2023. 24(3): p. 2978.
  73. Zhu, B., et al., Treatments in psoriasis: from standard pharmacotherapy to nanotechnology therapy. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 2022. 39(3): p. 460-471.
  74. Pegoraro, N.S., et al., The association of oleic acid and dexamethasone acetate into nanocapsules enables a reduction in the effective corticosteroid dose in a UVB radiation-induced sunburn model in mice. Pharmaceutics, 2024. 16(2): p. 176.
  75. Alnaim, A.S., Nanocrystals in Dermal Drug Delivery: A Breakthrough for Enhanced Skin Penetration and Targeted Skin Disorder Treatments. Pharmaceutics, 2024. 16(12): p. 1561.
  76. Kumar, S., M. Prasad, and R. Rao, Topical delivery of clobetasol propionate loaded nanosponge hydrogel for effective treatment of psoriasis: Formulation, physicochemical characterization, antipsoriatic potential and biochemical estimation. Materials Science and Engineering: C, 2021. 119: p. 111605.
  77. Kumar, S., B.L. Jangir, and R. Rao, Novel topical clobetasol propionate nanosponges loaded hydrogel for psoriasis: Irritation evaluation, mechanistic insights, in vivo appraisal and biochemical investigations. BioNanoScience, 2024. 14(2): p. 1749-1766.
  78. Tabarzad, M. and F. Ghorbani-Bidkorbeh, Dendrimers formulations to enhance skin drug delivery, in Dendrimer-based nanotherapeutics. 2021, Elsevier. p. 399-416.
  79. Biswasroy, P., et al., Recent advancement in topical nanocarriers for the treatment of psoriasis. Aaps Pharmscitech, 2021. 22(5): p. 164.
  80. Gomes, G.S., et al., Lipid core nanocapsules-loaded tacrolimus: Development and evaluation of quality parameters. Drug Analytical Research, 2022. 6(1): p. 46-57.
  81. Xu, J., et al., A multifunctional composite hydrogel as an intrinsic and extrinsic coregulator for enhanced therapeutic efficacy for psoriasis. Journal of Nanobiotechnology, 2022. 20(1): p. 155.
  82. Liu, Y., et al., Advances in the Drug Delivery Systems for Psoriasis Topical Therapy. International Journal of Nanomedicine, 2025: p. 12307-12329.
  83. Balogh, B., et al., Formulation and Evaluation of Different Nanogels of Tapinarof for Treatment of Psoriasis. Gels, 2024. 10(11): p. 675.
  84. Gowda, B.J., et al., Microneedles as a momentous platform for psoriasis therapy and diagnosis: A state-of-the-art review. International journal of pharmaceutics, 2023. 632: p. 122591.
  85. Sutar, A.D. and R. Shukla, Emerging smart microneedle technologies in psoriasis: convergence of nanocarriers, machine learning, and personalized delivery. RSC Pharmaceutics, 2025.
  86. Salgaonkar, S.P., et al., New Insights in Psoriasis Management using Herbal Drug Nanocarriers. Current Pharmaceutical Design, 2024. 30(32): p. 2550-2561.
  87. Gangwar, R.S., J.E. Gudjonsson, and N.L. Ward, Mouse models of psoriasis: a comprehensive review. Journal of Investigative Dermatology, 2022. 142(3): p. 884-897.
  88. Doppalapudi, S., et al., Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis. European journal of pharmaceutical sciences, 2017. 96: p. 515-529.
  89. Aggarwal, G., M. Nagpal, and G. Kaur, Development and comparison of nanosponge and niosome based gel for the topical delivery of tazarotene. Pharmaceutical nanotechnology, 2016. 4(3): p. 213-228.
  90. Sonawane, R., et al., Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis. Expert opinion on drug delivery, 2014. 11(12): p. 1833-1847.
  91. Viegas, J.S.R., et al., Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis. Drug delivery and translational research, 2020. 10(3): p. 646-660.
  92. Mao, K.-L., et al., Skin-penetrating polymeric nanoparticles incorporated in silk fibroin hydrogel for topical delivery of curcumin to improve its therapeutic effect on psoriasis mouse model. Colloids and Surfaces B: Biointerfaces, 2017. 160: p. 704-714.
  93. Suzuki, I.L., et al., TNFα siRNA delivery by nanoparticles and photochemical internalization for psoriasis topical therapy. Journal of Controlled Release, 2021. 338: p. 316-329.
  94. Kumar, R., et al., Efficacy of novel topical liposomal formulation of cyclosporine in mild to moderate stable plaque psoriasis: a randomized clinical trial. JAMA dermatology, 2016. 152(7): p. 807-815.
  95. Ramez, S.A., et al., Novel methotrexate soft nanocarrier/fractional erbium YAG laser combination for clinical treatment of plaque psoriasis. Artificial cells, nanomedicine, and biotechnology, 2018. 46(sup1): p. 996-1002.
  96. Gavra, D.I., et al., In vitro and human pilot studies of different topical formulations containing rosa species for the treatment of psoriasis. Molecules, 2022. 27(17): p. 5499.
  97. Lebwohl, M.G., et al., Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials. Jama, 2022. 328(11): p. 1073-1084.
  98. Agrawal, Y., K.C. Petkar, and K.K. Sawant, Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. International journal of pharmaceutics, 2010. 401(1-2): p. 93-102.
  99. Kolahdooz, H., et al., Niosomal curcumin suppresses IL17/IL23 immunopathogenic axis in skin lesions of psoriatic patients: a pilot randomized controlled trial. Life, 2023. 13(5): p. 1076.
  100. Ju, H.J., et al., Additional Use of Hyaluronic Acid-Based Dissolving Microneedle Patches to Treat Psoriatic Plaques: A Randomized Controlled Trial. Annals of Dermatology, 2025. 37(2): p. 105.